Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
|
|
Aclaris Therapeutics, Inc. (ACRS)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/22/2023 |
4
| Monahan Joseph (Chief Scientific Officer) has filed a Form 4 on Aclaris Therapeutics, Inc.|
Txns:
| Sold 6,000 shares
@ $7.3158, valued at
$43.9k
|
|
| 08/03/2023 |
4
| Manion Douglas J. (Pres and CEO) has filed a Form 4 on Aclaris Therapeutics, Inc.|
Txns:
| Paid exercise price by delivering 4,437 shares
@ $9.81, valued at
$43.5k
Exercised 15,575 restricted stock units
@ $0 |
|
| 07/05/2023 |
4
| Cawkwell Gail (Chief Medical Officer) has filed a Form 4 on Aclaris Therapeutics, Inc.|
Txns:
| Paid exercise price by delivering 5,407 shares
@ $10.37, valued at
$56.1k
Exercised 15,000 restricted stock units
@ $0 |
|
| 06/05/2023 |
4
| Humphries William D. (Director) has filed a Form 4 on Aclaris Therapeutics, Inc.|
Txns:
| Granted 15,750 options to buy
@ $8.7, valued at
$137k
Granted 4,660 restricted stock units
@ $0
Exercised 4,507 restricted stock units
@ $0 |
|
| 06/05/2023 |
4
| MILANO VINCENT (Director) has filed a Form 4 on Aclaris Therapeutics, Inc.|
Txns:
| Granted 15,750 options to buy
@ $8.7, valued at
$137k
Granted 4,660 restricted stock units
@ $0
Exercised 4,507 restricted stock units
@ $0 |
|
| 06/05/2023 |
4
| GOWEN MAXINE (Director) has filed a Form 4 on Aclaris Therapeutics, Inc.|
Txns:
| Granted 15,750 options to buy
@ $8.7, valued at
$137k
Granted 4,660 restricted stock units
@ $0
Exercised 4,507 restricted stock units
@ $0 |
|
| 06/05/2023 |
4
| Molineaux Christopher P. (Director) has filed a Form 4 on Aclaris Therapeutics, Inc.|
Txns:
| Granted 15,750 options to buy
@ $8.7, valued at
$137k
Granted 4,660 restricted stock units
@ $0
Exercised 4,507 restricted stock units
@ $0 |
|
| 06/05/2023 |
4
| Reasons Bryan M. (Director) has filed a Form 4 on Aclaris Therapeutics, Inc.|
Txns:
| Granted 15,750 options to buy
@ $8.7, valued at
$137k
Granted 4,660 restricted stock units
@ $0
Exercised 4,507 restricted stock units
@ $0 |
|
| 06/05/2023 |
4
| SCHIFF ANDREW N (Director) has filed a Form 4 on Aclaris Therapeutics, Inc.|
Txns:
| Granted 15,750 options to buy
@ $8.7, valued at
$137k
Granted 4,660 restricted stock units
@ $0
Exercised 4,507 restricted stock units
@ $0 |
|
| 06/05/2023 |
4
| Powell Andrew Kenneth William (Director) has filed a Form 4 on Aclaris Therapeutics, Inc.|
Txns:
| Granted 15,750 options to buy
@ $8.7, valued at
$137k
Granted 4,660 restricted stock units
@ $0
Exercised 4,507 restricted stock units
@ $0 |
|
| 06/05/2023 |
4
| Mehra Anand (Director) has filed a Form 4 on Aclaris Therapeutics, Inc.|
Txns:
| Granted 15,750 options to buy
@ $8.7, valued at
$137k
Granted 4,660 restricted stock units
@ $0
Exercised 4,507 restricted stock units
@ $0 |
|
| 03/17/2023 |
4
| Manion Douglas J. (Pres and CEO) has filed a Form 4 on Aclaris Therapeutics, Inc.|
Txns:
| Bought 6,300 shares
@ $7.8623, valued at
$49.5k
|
|
| 03/09/2023 |
4
| Manion Douglas J. (Pres and CEO) has filed a Form 4 on Aclaris Therapeutics, Inc.|
Txns:
| Bought 6,500 shares
@ $7.735, valued at
$50.3k
|
|
| 03/03/2023 |
4
| Walker Neal (Director) has filed a Form 4 on Aclaris Therapeutics, Inc.|
Txns:
| Sold 29,000 shares
@ $12.3651, valued at
$358.6k
Sold 30,240 shares
@ $12.6346, valued at
$382.1k
Exercised 96,150 restricted stock units
@ $0
Exercised 18,275 restricted stock units
@ $0
Exercised 24,000 restricted stock units
@ $0
Exercised 18,254 restricted stock units
@ $0 |
|
| 03/03/2023 |
4
| Monahan Joseph (Chief Scientific Officer) has filed a Form 4 on Aclaris Therapeutics, Inc.|
Txns:
| Sold 14,800 shares
@ $12.3665, valued at
$183k
Sold 16,037 shares
@ $12.6342, valued at
$202.6k
Exercised 13,750 restricted stock units
@ $0
Exercised 50,000 restricted stock units
@ $0
Exercised 10,925 restricted stock units
@ $0
Exercised 12,500 restricted stock units
@ $0 |
|
| 03/03/2023 |
4
| Balthaser Kevin (CFO) has filed a Form 4 on Aclaris Therapeutics, Inc.|
Txns:
| Sold 1,000 shares
@ $12.289, valued at
$12.3k
Sold 894 shares
@ $12.6281, valued at
$11.3k
Exercised 1,475 restricted stock units
@ $0
Exercised 1,100 restricted stock units
@ $0
Exercised 2,375 restricted stock units
@ $0
Exercised 1,500 restricted stock units
@ $0 |
|
| 02/10/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/03/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/03/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/03/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/03/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/03/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/03/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/20/2023 |
4
| Powell Andrew Kenneth William (Director) has filed a Form 4 on Aclaris Therapeutics, Inc.|
Txns:
| Gifted 4,000 shares
@ $0 |
|
| 01/06/2023 |
3
| Balthaser Kevin (CFO) has filed a Form 3 on Aclaris Therapeutics, Inc. |
| 01/04/2023 |
4
| Walker Neal (Director) has filed a Form 4 on Aclaris Therapeutics, Inc.|
Txns:
| Sold 23,382 shares
@ $15.1855, valued at
$355.1k
Sold 1,618 shares
@ $16.1594, valued at
$26.1k
Sold 15,000 shares
@ $14.8895, valued at
$223.3k
|
|
| 12/16/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/14/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/26/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/19/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/19/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/11/2022 |
4
| SCHIFF ANDREW N (Director) has filed a Form 4 on Aclaris Therapeutics, Inc.|
Txns:
| Sold 7,324 shares
@ $16.1591, valued at
$118.3k
|
|
| 10/06/2022 |
4
| SCHIFF ANDREW N (Director) has filed a Form 4 on Aclaris Therapeutics, Inc.|
Txns:
| Sold 7,700 shares
@ $16.0076, valued at
$123.3k
Sold 37,839 shares
@ $16.537, valued at
$625.7k
|
|
| 08/02/2022 |
4
| Manion Douglas J. (Pres and COO) has filed a Form 4 on Aclaris Therapeutics, Inc.|
Txns:
| Granted 217,800 options to buy
@ $13.62, valued at
$3M
Granted 62,300 restricted stock units
@ $0 |
|
|
|
|